According to DrugPatentWatch.com [1], a website that tracks patent information for pharmaceutical products, Apotex is developing a generic version of Ruxolitinib, an oral medication used to treat myelofibrosis and polycythemia vera.

Ruxolitinib is currently marketed under the brand name Jakafi, which is developed by Incyte Corporation and Novartis Pharmaceuticals. However, as of my knowledge cutoff in 2023, the patent for Jakafi is set to expire in the United States in April 2025 [2].

Based on the information available, it appears that Apotex's generic version of Ruxolitinib may become available on the market in April 2025, after the expiration of the patent for Jakafi. However, please note that this is an estimate and the actual availability of the generic product may be affected by various factors, including regulatory approvals and manufacturing timelines.

It's worth noting that the availability of generic medications can vary depending on the country and region. In some cases, generic medications may be available in certain countries before they are approved in others.

Source:
[1] DrugPatentWatch.com (https://www.drugpatentwatch.com/drug/ruxolitinib)

Sources:
1. DrugPatentWatch.com (https://www.drugpatentwatch.com/drug/ruxolitinib)
2. Patent expiration dates for Jakafi (Ruxolitinib) - DrugPatentWatch.com (https://www.drugpatentwatch.com/patent/jakafi-expiration)